Toni Weinschenk, Ph.D

Chief Technology Officer

Since more than fifteen years, Dr Toni Weinschenk is active in the field of cancer immunology with focus on discovery of HLA-presented peptides from native tumor and normal tissues by mass spectrometry. He is regarded the world’s leading expert in ultra-high sensitive, quantitative and high-throughput mass spectrometry of HLA ligands.

Toni Weinschenk co-founded Immatics Biotechnologies GmbH during his PhD studies and is the creator of the XPRESIDENT® target discovery engine for identification, selection and validation of TUMAPs (tumor-associated peptides) as therapeutic cancer vaccines as well as targets for antibody-, T-cell-receptor-based and cellular approaches.

At Immatics Biotechnologies GmbH, Toni Weinschenk heads the Discovery Department with approx. 20 FTEs dedicated to target discovery and validation. At Immatics US Inc., his role as Chief Technology Officer is to setup and run Immatics’ target discovery capabilities as biomarkers for clinical trials conducted in Houston, TX.

Toni Weinschenk studied biochemistry in Tuebingen and at the Max-Planck-Institute in Munich, Germany. His passion for HLA ligands and ligandomes developed during his PhD thesis in the lab of Hans-Georg Rammensee. Toni Weinschenk is inventor on many patents and co-authored publications in the cancer immunology field in peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Reports.